LH:NYE-Laboratory Corporation of America Holdings

EQUITY | Medical Diagnostics & Research | New York Stock Exchange

Last Closing Price

USD 150.17

Change

0.00 (0.00)%

Market Cap

USD 15.15B

Volume

1.66M

Average Target Price

USD 176.39 (+17.46%)
Average Analyst Rating

Verdict

STA Verdict

Verdict

About

Laboratory Corp of America Holdings is a healthcare diagnostics company. The Company along with its subsidiaries provides clinical laboratory services and end-to-end drug development support.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-02-16 )

Largest Industry Peers for Medical Diagnostics & Research

Symbol Name Price(Change) Market Cap
TMO Thermo Fisher Scientific Inc

N/A

USD 101.65B
DHR Danaher Corporation

N/A

USD 78.03B
PHG Koninklijke Philips N.V. NY Re..

N/A

USD 35.93B
IQV IQVIA Holdings Inc.

N/A

USD 28.09B
A Agilent Technologies Inc.

N/A

USD 24.87B
Q Quintiles IMS Holdings Inc.

N/A

USD 21.87B
WAT Waters Corporation

N/A

USD 17.78B
MTD Mettler-Toledo International I..

N/A

USD 16.58B
DGX Quest Diagnostics Incorporated

N/A

USD 11.95B
PKI PerkinElmer Inc.

N/A

USD 10.46B

ETFs Containing LH

Symbol Name Weight Mer Price(Change) Market Cap
IHF iShares U.S. Health Care .. 3.06 % 0.43 %

N/A

USD 0.96B
FHH.F:CA First Trust AlphaDEX U.S... 2.29 % 0.00 %

N/A

CAD 0.98M
FXH First Trust Health Care A.. 2.29 % 0.63 %

N/A

USD 2.13B

Market Performance

  Market Performance vs.
Industry/Classification (Medical Diagnostics & Research)
Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 18.84% 65% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 18.84% 65% D 80% B-
Trailing 12 Months  
Capital Gain -15.54% 24% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.54% 18% F 19% F
Trailing 5 Years  
Capital Gain 63.33% 50% F 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 63.33% 29% F 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 13.00% 47% F 85% B
Dividend Return 13.00% 41% F 82% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 12.14% 82% B- 59% F
Risk Adjusted Return 107.04% 53% F 88% B+
Market Capitalization 12.76B 59% F 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Diagnostics & Research)
Ratio vs. Market
(New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.24 71% C- 38% F
Price/Book Ratio 2.09 82% B- 38% F
Price / Cash Flow Ratio 2.90 82% B- 44% F
Price/Free Cash Flow Ratio 16.45 76% C 37% F
Management Effectiveness  
Return on Equity 16.62% 65% D 75% C
Return on Invested Capital 13.89% 71% C- 68% D+
Return on Assets 7.07% 71% C- 78% C+
Debt to Equity Ratio 69.50% 35% F 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector